Teva Pharmaceutical Industries Limited Statistics
Share Statistics
Teva Pharmaceutical Industries Limited has 1.13B shares outstanding. The number of shares has increased by 1.07% in one year.
| Shares Outstanding | 1.13B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.13B |
| Failed to Deliver (FTD) Shares | 63.02K |
| FTD / Avg. Volume | 0.93% |
Short Selling Information
The latest short interest is 18.09M, so 1.6% of the outstanding shares have been sold short.
| Short Interest | 18.09M |
| Short % of Shares Out | 1.6% |
| Short % of Float | 1.6% |
| Short Ratio (days to cover) | 3.5 |
Valuation Ratios
The PE ratio is -20.9 and the forward PE ratio is 6.19.
| PE Ratio | -20.9 |
| Forward PE | 6.19 |
| PS Ratio | 0.74 |
| Forward PS | 1.1 |
| PB Ratio | 1.56 |
| P/FCF Ratio | 13.87 |
| PEG Ratio | n/a |
Enterprise Valuation
Teva Pharmaceutical Industries Limited has an Enterprise Value (EV) of 28.61B.
| EV / Earnings | -51.18 |
| EV / Sales | 1.81 |
| EV / EBITDA | 18.22 |
| EV / EBIT | 66.07 |
| EV / FCF | 33.98 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 2.64.
| Current Ratio | 1.02 |
| Quick Ratio | 0.69 |
| Debt / Equity | 2.64 |
| Total Debt / Capitalization | 72.54 |
| Cash Flow / Debt | 0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is 1.51%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.01% |
| Return on Capital (ROIC) | 1.51% |
| Revenue Per Employee | 428.27K |
| Profits Per Employee | -15.11K |
| Employee Count | 37.00K |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | -7.00M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 65.13% in the last 52 weeks. The beta is 0.87, so Teva Pharmaceutical Industries Limited's price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | 65.13% |
| 50-Day Moving Average | 17.53 |
| 200-Day Moving Average | 16.44 |
| Relative Strength Index (RSI) | 43.22 |
| Average Volume (20 Days) | 6.74M |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries Limited had revenue of $15.85B and earned -$559.00M in profits. Earnings per share was $-0.5.
| Revenue | 15.85B |
| Gross Profit | 7.65B |
| Operating Income | 433.00M |
| Net Income | -559.00M |
| EBITDA | 1.57B |
| EBIT | 433.00M |
| Earnings Per Share (EPS) | -0.5 |
Balance Sheet
The company has $3.23B in cash and $20.15B in debt, giving a net cash position of -$16.93B.
| Cash & Cash Equivalents | 3.23B |
| Total Debt | 20.15B |
| Net Cash | -16.93B |
| Retained Earnings | -13.53B |
| Total Assets | 41.76B |
| Working Capital | -1.48B |
Cash Flow
In the last 12 months, operating cash flow was $1.37B and capital expenditures -$526.00M, giving a free cash flow of $842.00M.
| Operating Cash Flow | 1.37B |
| Capital Expenditures | -526.00M |
| Free Cash Flow | 842.00M |
| FCF Per Share | 0.75 |
Margins
Gross margin is 48.25%, with operating and profit margins of 2.73% and -3.53%.
| Gross Margin | 48.25% |
| Operating Margin | 2.73% |
| Pretax Margin | -3.94% |
| Profit Margin | -3.53% |
| EBITDA Margin | 9.91% |
| EBIT Margin | 2.73% |
| FCF Margin | 5.31% |
Dividends & Yields
TEVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.03% |
| FCF Yield | 4.5% |
Analyst Forecast
The average price target for TEVA is $20.5, which is 24.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.5 |
| Price Target Difference | 24.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Jul 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 0.27 |
| Piotroski F-Score | 5 |